Mitomicin Accord (Mitomycin)

Mitomycin, the active ingredient in Mitomicin Accord, is an antineoplastic agent presented as an injectable formulation for intravenous use. It is employed in chemotherapy protocols to treat several solid tumours, including bladder, gastric, breast, cervical and pancreatic cancers, primarily in adult oncology patients.

GNH USA supplies Mitomicin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product complies with EU regulatory requirements and is manufactured under GMP conditions, ensuring consistent potency and safety for global distribution.

Mitomicin Accord (mitomycin) is employed in chemotherapy for solid tumours.

- Bladder cancer: improves local disease control and may reduce recurrence after surgery. - Gastric cancer: contributes to tumour shrinkage and enhances resectability. - Breast cancer: used in combination regimens to target resistant disease. - Cervical cancer: provides cytotoxic activity against malignant cells. - Pancreatic cancer: adds to multi‑agent protocols to prolong survival.

Mitomicin Accord may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Myelosuppression: reduced white blood cells, red blood cells, and platelets. - Mucositis: inflammation of the mouth and gastrointestinal lining. - Fatigue: persistent tiredness affecting daily activities. - Renal toxicity: impaired kidney function in some patients.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue. - Severe hemorrhage: bleeding complications due to thrombocytopenia. - Anaphylactic reaction: rare hypersensitivity requiring immediate medical attention. - Secondary malignancies: potential development of new cancers after prolonged exposure. - Hepatotoxicity: liver enzyme elevations or dysfunction.

Mitomicin Accord requires careful monitoring and adherence to safety guidelines. - Baseline assessment: obtain complete blood count and renal function before initiation. - Monitoring: perform regular hematologic and renal tests during therapy. - Hydration: ensure adequate fluid intake to support kidney clearance. - Contraindications: avoid use in patients with known hypersensitivity to mitomycin. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomicin Accord can interact with other medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP450 inducers: may reduce mitomycin plasma levels. - Anticoagulants: increase risk of severe bleeding.

Moderate Interactions (Monitor Closely): - Other alkylating agents: additive myelosuppression. - Nephrotoxic drugs: heightened renal toxicity. - Radiotherapy: enhanced tissue damage when combined. - NSAIDs: potential for increased gastrointestinal irritation. - Immunosuppressants: may exacerbate infection risk.